Hering Dagmara, Marusic Petra, Duval Jacqueline, Sata Yusuke, Head Geoffrey A, Denton Kate M, Burrows Sally, Walton Antony S, Esler Murray D, Schlaich Markus P
School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia, Australia.
Neurovascular Hypertension & Kidney Disease Laboratory, Baker IDI Heart & Diabetes Institute, Melbourne, Australia.
Int J Cardiol. 2017 Apr 1;232:93-97. doi: 10.1016/j.ijcard.2017.01.047. Epub 2017 Jan 6.
Renal denervation (RDN) can reduce blood pressure (BP) and slow the decline of renal function in chronic kidney disease (CKD) up to one year. Whether this effect is maintained beyond 12months and whether the magnitude of BP reduction affects estimated glomerular filtration rate (eGFR) is unknown.
We examined eGFR in 46 CKD patients (baseline eGFR ≤60mL/min/1.73m) on a yearly basis from 60months before to 3, 6, 12 and 24months after RDN. Ambulatory BP was measured before and after RDN. Linear mixed models analysis demonstrated a significant progressive decline in eGFR from months 60 to 12months (-15.47±1.98mL/min/1.73m, P<0.0001) and from 12months to baseline prior to RDN (-3.41±1.64mL/min/1.73m, P=0.038). Compared to baseline, RDN was associated with improved eGFR at 3months (+3.73±1.64mL/min/1.73m, P=0.02) and no significant changes at 6 (+2.54±1.66mL/min/1.73m, P=0.13), 12 (+1.78±1.64mL/min/1.73m, P=0.28), and 24 (-0.24±2.24mL/min/1.73m, P=0.91) months post procedure were observed. RDN significantly reduced daytime SBP from baseline to 24months post procedure (148±19 vs 136±17mmHg, P=0.03) for the entire cohort. Changes in SBP were unrelated to the eGFR changes at 6 (r=0.033, P=0.84), 12 (r=0.01, P=0.93) and 24months (r=-0.42, P=0.17) follow-up.
RDN can slow further deterioration of renal function irrespective of BP lowering effects in CKD. RDN-induced inhibition of sympathetic outflow to the renal vascular bed may account for improved eGFR via alterations of intrarenal and glomerular hemodynamics.
肾去神经支配术(RDN)可降低血压(BP),并在长达一年的时间内减缓慢性肾脏病(CKD)患者肾功能的下降。这种效果在12个月后是否能持续,以及血压降低的幅度是否会影响估计肾小球滤过率(eGFR)尚不清楚。
我们对46例CKD患者(基线eGFR≤60mL/min/1.73m²)在RDN术前60个月至术后3、6、12和24个月期间每年检查其eGFR。在RDN术前和术后测量动态血压。线性混合模型分析显示,从60个月至12个月eGFR显著逐渐下降(-15.47±1.98mL/min/1.73m²,P<0.0001),从12个月至RDN术前基线时也下降(-3.41±1.64mL/min/1.73m²,P=0.038)。与基线相比,RDN术后3个月eGFR有所改善(+3.73±1.64mL/min/1.73m²,P=0.02),而在6个月(+2.54±1.66mL/min/1.73m²,P=0.13)、12个月(+1.78±1.64mL/min/1.73m²,P=0.28)和24个月(-0.24±2.24mL/min/1.73m²,P=0.91)时未观察到显著变化。对于整个队列,RDN显著降低了术后24个月时的日间收缩压(SBP)(从基线时的148±19mmHg降至136±17mmHg,P=0.03)。SBP的变化与6个月(r=0.033,P=0.84)、12个月(r=0.01,P=0.93)和24个月(r=-0.42,P=0.17)随访时的eGFR变化无关。
在CKD中,无论血压降低效果如何,RDN均可减缓肾功能的进一步恶化。RDN诱导的对肾血管床交感神经传出的抑制可能通过改变肾内和肾小球血流动力学来解释eGFR的改善。